Abstracts Archive - Page 630 of 2425 - ACR Meeting Abstracts

Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Xenofon Baraliakos¹, Roberto Ranza², Andrew Ostor³, Francesco Ciccia⁴, Laura Coates⁵, Simona Rednic⁶, Jessica Walsh⁷, Tianming Gao⁸, Apinya Lertratanakul⁸, In-Ho Song⁸, Fabiana Ganz⁸, Kevin Douglas⁸ and Atul Deodhar⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ³Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁴University of Campania Luigi Vanvitelli, Napoli, Italy, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸AbbVie Inc., North Chicago, IL, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Xenofon Baraliakos¹, Effie Pournara², Laura Coates³, Victoria Navarro-Compán⁴, Roisin White⁵, Barbara Schulz² and Robert Landewé⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Katie Roberts, Annapolis, MD
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: PP04 • ACR Convergence 2021
Dual Roles: Thriving with SLE as a Medical Student
Chieh Lo¹ and Song-Chou Hsieh², ¹School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), ²Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Guadalupe Torres¹, Courtney Wells² and Kristine Carandang³, ¹, ²University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, ³Global Healthy Living Foundation, CreakyJoints, San Diego, CA
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: 1866 • ACR Convergence 2021
Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients
Bradly Kimbrough¹, Kenneth Warrington², Hannah Langenfeld³, Cynthia Crowson⁴, Eva Carmona³, Andrew Virata³ and Matthew Koster³, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Vasculitis in patients with sarcoidosis is rare and can affect blood vessels of any size. Limited information describing this association is available. The purpose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].